ADQI 7: The clinical management of the Cardio-Renal syndromes: Work group statements from the 7th ADQI consensus conference

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2077-2089

  Davenport, A ^a   Anker, S D ^b   Mebazaa, A ^c   Palazzuoli, A ^d   Vescovo, G ^e   Bellomo, R ^f   Ponikowski, P ^g   Anand, I ^h   Aspromonte, N ⁱ   Bagshaw, S ^j   Berl, T ^k   Bobek, I ^e   Cruz, D N ^e   Daliento, L ^l   Haapio, M ^m   Hillege, H ⁿ   House, A ^o   Katz, N ^p   Maisel, A ^h   Mankad, S ^q   McCullough, P ^r   Ronco, F ^l   Shaw, A ^s   Sheinfeld, G ^t   Soni, S ^u   Zamperetti, N ^e   Zanco, P ^e   Ronco, C ^e   more..

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e SAN BORTOLO HOSPITAL   (Italy)

^f AUSTIN HOSPITAL   (Australia)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ SAN FILIPPO NERI HOSPITAL   (Italy)

^j UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF PADOVA   (Italy)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o LONDON HEALTH SCIENCES CENTRE   (Canada)

^p GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^q MAYO CLINIC   (United States)

^r WILLIAM BEAUMONT HOSPITAL   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t R ADAMS COWLEY SHOCK TRAUMA CENTER   (United States)

^u Mediciti Hospitals   (India)

more..

Author keywords

cardio renal; chronic kidney disease; heart failure; ischaemic heart disease; renal failure

Indexed keywords

ADRENALIN; ALDOSTERONE ANTAGONIST; ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXIMONE; HYDRALAZINE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; IRON; LEVOSIMENDAN; MILRINONE; MORPHINE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; NORADRENALIN; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST; WARFARIN;

ACUTE DIALYSIS QUALITY INITIATIVE; ANAPHYLAXIS; ASTHMA; BLOOD TOXICITY; BRADYCARDIA; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CONSENSUS; CORONARY ARTERY DISEASE; CYANIDE POISONING; DIZZINESS; GOUT; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENOCARDIAC SYNDROME; RESPIRATION DEPRESSION; REVIEW; SKIN TOXICITY; TOXICITY; COMPLICATION; CONSENSUS DEVELOPMENT; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; SYNDROME;

HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY; SYNDROME;

EID: 77954321305     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq252     Document Type: Review

References (144)

1. European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM) et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail 2008; 10: 933-989
2. Ronco C, Anker S, McCullough P et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31: 703-711
3. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments and outcomes of patients with preserved systolic function hospitalised for heart failure. A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-777
4. Nicol ED, Fittall B, Roughton M et al. NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart 2008; 94: 172-177
5. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12: 91-95
6. Zannad F, Mebazaa A, Juillière Y et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006; 8: 697-705
7. Mullens W, Abrahams Z, Francis GS et al. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail 2008; 14: 508-514
8. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure\definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004; 8: R204-R212
9. Ronco C, Levin A, Wanock DG et al. Improving outcomes of acute kidney injury (AKI): report on an initiative. Int J Artif Organs 2007; 30: 373-376 (Pubitemid 47072692)
10. Cotter G, Metra M, Milo-Cotter O et al. Fluid overload in acute heart failure\re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008; 10: 165-169
11. Raizada V, Skipper B, Luo W et al. Intracardiac and intrarenal re-nin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 2007; 55: 341-359
12. Burchill L, Velkoska E, Dean RG et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol 2008; 93: 622-630
13. Textor SC, Wilcox CS. Renal artery stenosis: a common treatable cause of renal failure? Ann Rev Med 2001; 52: 421-442
14. Cingolani HE, Ennis IL. Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 2007; 115: 1090-1100
15. Schoner W, Scheiner-Bobis G. Role of endogenous cardiotonic steroids in sodium homeostasis. Nephrol Dial Transplant 2008; 23: 2723-2729
16. Titze J, Shakibaei M, Schafflhuber M et al. Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin. Am J Physiol Heart Circ Physiol 2004; 287: H203-H208
17. Locatelli F, Pozzoni P, Del Vecchio L. Anemia and heart failure in chronic kidney disease. Semin Nephrol 2005; 25: 392-396
18. Davenport A. Intradialytic complications during haemodialysis. Hemodial Int 2006; 10: 162-167
19. Remppis A, Ritz E. Cardiac problems in the dialysis patient. Beyond coronary artery disease. Seminars Dialysis 2008; 21: 319-325
20. Kellum JA, Mehta RL, Levin A et al. Development of a clinical research agenda for acute kidney injury using an international instep modified Delphi process. Clin J Am Soc Nephrol 2008; 3: 887-894
21. Kellum JA, Belomo R, Ronco C. Acute dialysis quality initiative (ADQI) methodology. Int J Artif Organs 2008; 31: 90-93
22. Cupples WA, Braam B. Assessment of renal autoregulation. Am J Physiol Renal Physiol 2007; 292: 1105-1112
23. Erdos G, Tzanova I, Schirmer U et al. Neuromonitoring and neuro-protection in cardiac anaesthesia. Nationwide survey conducted by the cardiac anaesthesia working group of the German society of anaesthesiology and intensive care medicine. Anaesthesist 2009; 58: 247-258
24. Hamada H, Nakagawa I, Uesugi F et al. [Effects of perfusion pressure on cerebral blood flow and oxygenation during normothermic cardiopulmonary bypass]. Masui 2004; 53: 744-752
25. de Silva R, Nikitin NP, Witte KK et al. Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure. Eur J Heart Fail 2007; 9: 415-423
26. Elkayam U, Janmohamed M, Habib M et al. Vasodilators in the management of acute heart failure. Crit Care Med 2008; 36: S95-S105
27. Hollenberg SM. Vasodilators in acute heart failure. Heart Fail Rev 2007; 12: 143-147
28. Sackner-Bernstein J, Skopicki HA, Aaronson KD. Risk of worsening renal function in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491 (Pubitemid 40470642)
29. Yancy CW, Krum H, Massie BM et al. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J 2007; 153: 478-484
30. Owan TE, Chen HH, Frantz RP et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail 2008; 14: 267-275
31. Lüss H, Mitrovic V, Seferovic PM et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008; 155: 1012.e1-8
32. Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med 2008; 36: S89-S94
33. Cotter OM, Sasimangalam AN, Arumugham PS et al. Diuretics\a panacea for acute heart failure? Different formulations, doses, and combinations. Heart Fail Monit 2008; 6: 9-19
34. Hasselblad V, Gattis Stough W, Shah MR et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064-1069
35. Costanzo MR, Johannes RS, Pine M et al. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J 2007; 154: 267-277
36. Heywood JT, Khan TA. The use of vasoactive therapy for acute de-compensated heart failure: hemodynamic and renal considerations. Rev Cardiovasc Med 2007; 8: S22-S29
37. Rajaram V, Joseph J. Role of adenosine antagonism in the cardio-renal syndrome: pathophysiology and therapeutic potential. Curr Heart Fail Rep 2007; 4: 153-157
38. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006; 110: 386-414
39. Givertz MM, Massie BM, Fields TK et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007; 50: 1551-1660
40. Ho JE, Teerlink JR. Role of tolvaptan in acute decompensated heart failure. Expert Rev Cardiovasc Ther 2008; 6: 601-608
41. Veeraveedu PT, Watanabe K, Ma M et al. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Biochem Pharmacol 2008; 75: 1322-1330
42. Bishara B, Shiekh H, Karram T et al. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. J Pharmacol Exp Ther 2008; 326: 414-422
43. Blair JE, Khan S, Konstam MA et al. Weight changes after hos-pitalisation for worsening heart failure and subsequent rehospita-lisation and mortality in the EVEREST trial. Eur Heart J 2009; 30: 1166-1173
44. Gibney N, Cerda J, Davenport A et al. Volume management by renal replacement therapy in acute kidney injury. Int J Artif Organs 2008; 31: 145-155 (Pubitemid 351425011)
45. Nieminen MS, Brutsaert D, Dickstein K et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736
46. Hasei M, Uchiyama A, Nishimura M et al. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease. Acta Anaesthesiol Scand 2008; 52: 991-996
47. Yilmaz MB, Yalta K, Yontar C et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007; 21: 431-435
48. Puttonen J, Kantele S, Kivikko M et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007; 46: 235-246
49. Arora RR, Shah AG. Enhanced external counterpulsation: a new modality in the treatment of angina and heart failure. J Cardiovasc Pharmacol Ther 2006; 11: 271-273
50. Tatsumi E, Nakatani T, Imachi K et al. Domestic and foreign trends in the prevalence of heart failure and the necessity of next-generation artificial hearts: a survey by the Working Group on Establishment of Assessment Guidelines for Next-Generation Artificial Heart Systems. J Artif Organs 2007; 10: 187-194
51. Hermansen SE, Hansen M, Roaldsen M et al. How many acute heart failure patients need a ventricular assist device? Scand Cardi-ovasc J 2008; 42: 118-124
52. de Jonge N, Kirkels JH, Klöpping C et al. Guidelines for heart transplantation. Neth Heart J 2008; 16: 79-87
53. Allen LA, Felker GM. The Surgical Treatment for Ischemic Heart failure study. Opin Cardiol 2008; 23: 249-253
54. Blair JE, Macarie C, Ruzyllo W et al. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of is-taroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther 2008; 15: 231-240
55. Heart Failure Society of America. Nonpharmacologic management and health care maintenance in patients with chronic heart failure. J Card Fail 2006; 12: e29-e37
56. Ershow AG, Costello RB. Dietary guidance in heart failure: a perspective on needs for prevention and management. Heart Fail Rev 2006; 11: 7-12
57. Anker SD, John M, Pedersen PU et al. ESPEN Guidelines on En-teral Nutrition: Cardiology and pulmonology. Clin Nutr 2006; 25: 311-318
58. Whellan DJ, O?Connor CM, Lee KL et al. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J 2007; 153: 201-211
59. Jaarsma T, van der Wal MH, Lesman-Leegte I et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counselling in Heart Failure (COACH). Arch Intern Med 2008; 168: 316-324
60. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435
61. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302
62. McAlister FA, Stewart S, Fettua S et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomised trials. J Am Coll Cardiol 2004; 44: 810-819
63. Bangalore S, Messerli FH, Kostis JB et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50: 563-572
64. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
65. [Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007
66. Parker M, Coats AJ, Fowler MB et al. Effect of carvediliol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658
67. Weir RA, McMurray JJ, Puu M et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldoste-rone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10: 157-163
68. Struthers A, Krum H, Williams GH. A comparison of the aldoste-rone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153-158
69. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortaslity in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
70. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675
71. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766 (Pubitemid 37093915)
72. McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47: 726-733
73. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906
74. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008; 14: 181-188
75. The ONTARGET investigators. Telmisartan, Ramipril or both in patients with high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
76. Cowan BR, Young AA, Anderson C et al. Left ventricular mass and volume with telmisartan, ramipril, r combination in patients with previous atherosclerotic events or with diabetes mellitus (from the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET). Am J Cardiol 2009; 104: 1484-1489
77. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049-2057
78. The Digitalis Investigation Group. The effect of digoxoin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533
79. Vardas PE, Auricchio A, Blanc JJ et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007; 28: 2256-2295
80. Barnett D, Phillips S, Longson C. Cardiac resynchronisation therapy for the treatment of heart failure: NICE technology appraisal guidance. Heart 2007; 93: 1134-1135
81. Piccini JP, Hernandez AF, Dai D et al. Use of cardiac resynchroniza-tion therapy in patients hospitalized with heart failure. Circulation 2008; 118: 926-933
82. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised double blind placebo controlled trial. Lancet 2008; 372: 1231-1239
83. Kjekshus J, Apetrei E, Barrios Vet al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261
84. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised double blind placebo controlled trial. Lancet 2008; 372: 1223-1230
85. Allen LA, Felker GM. Advances in the surgical treatment of heart failure. Curr Opin Cardiol 2008; 23: 249-253
86. Jacques F, Carrier M, Pelletier GB et al. Two decades of cardiac transplantation at the Montreal Heart Institute. Can J Cardiol 2008; 24: 217-221
87. Tjang YS, van der Heijden GJ, Tenderich G et al. Survival analysis in heart transplantation: results from an analysis of 1290 cases in a single center. Eur J Cardiothorac Surg 2008; 33: 856-861
88. Shams OF, Ventura HO. Device therapy for heart failure: when and for whom? Am J Cardiovasc Drugs 2008; 8: 147-153
89. Brieke A, Cleveland J Jr, Lindenfeld J. Mechanical support in acute and chronic heart failure. Curr Cardiol Rep 2008; 10: 168-175
90. Matthews JC, Dardas TF, Dorsch MP et al. Right-sided heart failure: diagnosis and treatment strategies. Curr Treat Options Cardiovasc Med 2008; 10: 329-341
91. Catapano-Minotti G, Corsonello A, Guadalupi G et al. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Intern Med 2008; 47: 511-513
92. Metra M, Nodari S, Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008; 10: 188-195
93. Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18: 2766-2772
94. Coca SG, Krumholz HM, Garg AX et al. Under representation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384
95. Kaisar MO, Isbel NM, Johnson DW. Recent clinical trials of phar-macologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials 2008; 3: 79-88
96. Komukai K, Ogawa T, Yagi H et al. Decreased renal function as an independent predictor of re-hospitalization for congestive heart failure. Circ J 2008; 72: 1152-1157
97. Mahesh B, Yim B, Robson D et al. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furose-mide in patients with chronic kidney disease. Nephrology (Carlton) 2008; 13: 247-250
98. Ostermann M, Alvarez G, Sharpe MD et al. Frusemide administration in critically ill patients by continuous compared to bolus therapy. Nephron Clin Pract 2007; 107: c70-c76
99. Mielniczuk LM, Tsang SW, Desai AS et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008; 14: 388-393
100. Teiwes J, Toto RD. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens 2007; 20: 109-117
101. Cano N, Fiaccadori E, Tesinsky Pet al. ESPEN guidelines on enteral nutrition: adult renal failure. Clin Nutrition 2006; 25: 295-310
102. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril or both, in people at high vascular risk(the ON-TARGET study): a multicentre, randomised, double blind, controlled trial. Lancet 2008; 372: 547-553
103. Mann JFE, Schmieder RE, Dyal et al. Effect of telmisartan on renal outcomes: a randomised trial. Ann Intern Med 2009; 151: 1-10
104. Libetta C, Sepe V, Zucchi M et al. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 2007; 22: 2013-2019
105. Davenport A. Ultrafiltration in diuretic-resistant volume overload in nephritic syndrome and patients with ascites due to chronic liver disease. Cardiology 2001; 96: 190-195
106. Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation 2008; 117: 975-983
107. Costanzo MR. The role of ultrafiltration in the management of heart failure. Congest Heart Fail 2008; 14: 19-24
108. Rogers HL, Marshall J, Bock J et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furose-mide in patients with acute decompensated heart failure. J Card Fail 2008; 14: 1-5
109. Costanzo MR, Guglin ME, Saltzberg MTet al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompen-sated heart failure. J Am Coll Cardiol 2007; 49: 675-683
110. Gura V, Ronco C, Nalesso F et al. A wearable hemofilter for continuous ambulatory ultrafiltration. Kidney Int 2008; 73: 497-502
111. Wasse H, Gillen DL, Ball AM et al. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 2003; 64: 1455-1461 (Pubitemid 37153813)
112. Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-164
113. To AC, Yehia M, Collins JF. Atrial fibrillation in hemodialysis patients: do the guidelines for anticoagulation apply? Nephrology (Carlton) 2007; 12: 441-447
114. Holden RM, Harman GJ, Wang M et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 105-110
115. Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007; 50: 433-440
116. Anker SD, Voors A, Okonko D et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute mycocardial infarction: data from the OPTIMAAL trial. Eur Heart J 2009; 11: 1331-1339
117. Anker SD, Colet JC, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
118. Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007; 49: 753-762
119. Palazzuoli A, Silverberg D, Lovine F et al. Effects of ß-erythropoietin treatment on left ventricular remodelling, systolic function and B-type natriuretic peptide levels in patients with the cardio-renal anemia syndrome. Am Heart J 2007; 154: e9-e15
120. Parissis JT, Kourea K, Panou F et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008; 155: e1-e751
121. van Veldhuisen DJ, Dickstein K, Cohen-Solal A et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007; 28: 2208-2211
122. Hampl H, Hennig L, Rosenberger C et al. Optimized heart failure therapy and complete anemia correction on left-ventricular hypertrophy in nondiabetic and diabetic patients undergoing hemodialysis. Kidney Blood Press Res 2005; 28: 353-362
123. Yang JH, Cheng LT, Gu Y et al. Volume overload in patients treated with continuous ambulatory peritoneal dialysis associated with reduced circadian blood pressure variation. Blood Purif 2008; 26: 399-403
124. Davenport A. Audit of the effect of dialysate sodium concentration on inter-dialytic weight gains and blood pressure control in chronic haemodialysis patients. Nephron Clin Pract 2006; 104: c120-c125
125. Zager PG, Nikolic J, Brown RH et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54: 561-569
126. Port FK, Hulbert-Shearon TE, Wolfe RA et al. Predialysis blood pressure and mortality risk in a national sample of maintenance haemodialysis patients. Am J Kid Dis 1999; 33: 507-517
127. Davenport A. Blood pressure measurements in haemodialysis patients. Kidney Int 2008; 73: 1092-1093
128. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2: 1228-1234
129. Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008; 73: 759-764
130. Davenport A, Cox C, Thuraisingham R. The importance of dialysate sodium concentration in determining interdialytic weight gains in chronic hemodialysis patients: the PanThames Renal Audit. Int J Artif Organs 2008; 31: 411-417
131. Davenport A, Cox C, Thuraisingham R. Blood pressure control and symptomatic intradialtytic hypotension in diabetic haemodialysis patients: a cross sectional survey. Nephron Clin Pract 2008; 109: c65-c71
132. Selby NM, McIntyre CW. The acute cardiac effects of dialysis. Semin Dial 2007; 20: 220-228
133. Lass P, Buscombe JR, Harber M et al. Cognitive impairment in patients with renal failure is associated with multiple-infarct dementia. Clin Nuclear Medicine 1999; 24: 561-565
134. Gowdak LHW, Arantes RL, de Paula FJ et al. Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail 2007; 29: 559-565
135. Gowdak LH, Arantes RL, de Paula FJ et al. beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004; 164: 2465-2471
136. Cice G, Ferrara L, D?Andrea A et al. Carvedilol increases two year survival in dialysis patients with dilated cardiomyopathy, a prospective placebo controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444
137. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1241-1248
138. Takei T, Otsubo S, Uchida K et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic hemodialysis. Nephron Clin Pract 2008; 108: c278-c288
139. Spalding EM, Chandna SM, Davenport A et al. Kt/V underestimates the haemodialysis dose in women and small men. Kidney Int 2008; 74: 348-355
140. Banerjee A, Davenport A. Changing patterns of pericardial disease in patients with end-stage renal disease. Hemodial Int 2006; 10: 249-255
141. Tordoir J, Canaud B, Haage P et al. European Best Practice Guidelines on vascular access. Nephrol Dial Transplant 2007; 22: 88-117
142. Basile C, Lomonte C, Vernaglione L et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23: 282-287
143. Cridlig J, Selton-Suty C, Alla F et al. Cardiac impact of the arterio-venous fistula after kidney transplantation: a case-controlled, match-paired study. Transpl Int 2008; 21: 948-954
144. Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes Controversies Conference. Kidney Int 2010; 77: 273-284